BCM
QNCX icon

BML Capital Management’s Quince Therapeutics QNCX Stock Holding History

BML Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,059
Closed -$2.12M – 30
2023
Q2 		$2.12M Buy
+7,059
New +$2.2M 1.91% 13

Other funds holding QNCX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BML Capital Management's QNCX Position: Q3 2023 in Review

BML Capital Management sold out of Quince Therapeutics (QNCX) in Q3 2023, closing a stake of 7,059 shares — an estimated $2.12M sold.

BML Capital Management first reported a position in QNCX in Q2 2023 and held it in 1 quarter. The position peaked at $2.12M in Q2 2023. 40 funds tracked by Wall St. Rank hold QNCX as of Q3 2023.

  • BML Capital Management reported no remaining Quince Therapeutics position as of Q3 2023 after selling out during the quarter.
  • BML Capital Management sold 7,059 Quince Therapeutics shares in Q3 2023, an estimated $2.12M.
  • BML Capital Management first reported a position in Quince Therapeutics in Q2 2023 and held it in 1 quarter.
  • BML Capital Management's Quince Therapeutics position peaked at $2.12M in Q2 2023.
  • 40 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2023.

Based on BML Capital Management's 13F filing for Q3 2023, filed 23 Oct 2023.